Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses. More below 👇 1/11

Two doses of ChAdOx1-S or BNT162b2 vaccine have high effectiveness against hospitalization & death at 20+ weeks after vaccination. Protection against infection waned. Waning greater in older persons and those with underlying risk factors. #COVID19Vaccines nej.md/3JKAOsx

Our paper on the effectiveness of the booster vaccines against symptomatic disease, hospitalisation and death after Delta infection has been now been peer-reviewed and is out in print👉

Our peer-reviewed paper estimating vaccine effectiveness against symptomatic disease with Omicron is now out! nejm.org/doi/full/10.10…

Rest in peace long boi❤️❤️❤️

Great news for RSV prevention in England! The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults. gov.uk/government/pub…